Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 48

1.

Metabolomic analysis of simvastatin and fenofibrate intervention in high-lipid diet-induced hyperlipidemia rats.

Xu QY, Liu YH, Zhang Q, Ma B, Yang ZD, Liu L, Yao D, Cui GB, Sun JJ, Wu ZM.

Acta Pharmacol Sin. 2014 Oct;35(10):1265-73. doi: 10.1038/aps.2014.72. Epub 2014 Sep 15.

2.

Hepatic insulin receptor deficiency impairs the SREBP-2 response to feeding and statins.

Miao J, Haas JT, Manthena P, Wang Y, Zhao E, Vaitheesvaran B, Kurland IJ, Biddinger SB.

J Lipid Res. 2014 Apr;55(4):659-67. doi: 10.1194/jlr.M043711. Epub 2014 Feb 10.

3.

Sustained and selective suppression of intestinal cholesterol synthesis by Ro 48-8071, an inhibitor of 2,3-oxidosqualene:lanosterol cyclase, in the BALB/c mouse.

Chuang JC, Valasek MA, Lopez AM, Posey KS, Repa JJ, Turley SD.

Biochem Pharmacol. 2014 Apr 1;88(3):351-63. doi: 10.1016/j.bcp.2014.01.031. Epub 2014 Jan 31.

4.

Antiobesity and vasoprotective effects of resveratrol in apoE-deficient mice.

Jeon SM, Lee SA, Choi MS.

J Med Food. 2014 Mar;17(3):310-6. doi: 10.1089/jmf.2013.2885. Epub 2014 Jan 16.

5.

Hypolipidemic effect of gypenosides in experimentally induced hypercholesterolemic rats.

Yang YH, Yang J, Jiang QH.

Lipids Health Dis. 2013 Oct 25;12:154. doi: 10.1186/1476-511X-12-154.

6.

Effect of 7-difluoromethyl-5, 4'-dimethoxygenistein on aorta atherosclerosis in hyperlipidemia ApoE(-/-) mice induced by a cholesterol-rich diet.

Zhang Y, Li L, You J, Cao J, Fu X.

Drug Des Devel Ther. 2013 Apr 3;7:233-42. doi: 10.2147/DDDT.S37512. Print 2013.

7.

Simvastatin suppresses vascular inflammation and atherosclerosis in ApoE(-/-) mice by downregulating the HMGB1-RAGE axis.

Liu M, Yu Y, Jiang H, Zhang L, Zhang PP, Yu P, Jia JG, Chen RZ, Zou YZ, Ge JB.

Acta Pharmacol Sin. 2013 Jun;34(6):830-6. doi: 10.1038/aps.2013.8. Epub 2013 Apr 8.

8.

Inhibitory effect of the combination therapy of simvastatin and pinocembrin on atherosclerosis in ApoE-deficient mice.

Sang H, Yuan N, Yao S, Li F, Wang J, Fang Y, Qin S.

Lipids Health Dis. 2012 Dec 5;11:166. doi: 10.1186/1476-511X-11-166.

9.

miR-33 controls the expression of biliary transporters, and mediates statin- and diet-induced hepatotoxicity.

Allen RM, Marquart TJ, Albert CJ, Suchy FJ, Wang DQ, Ananthanarayanan M, Ford DA, Baldán A.

EMBO Mol Med. 2012 Sep;4(9):882-95. doi: 10.1002/emmm.201201228. Epub 2012 Jul 5.

10.

No evidence for mevalonate shunting in moderately affected children with Smith-Lemli-Opitz syndrome.

Roullet JB, Merkens LS, Pappu AS, Jacobs MD, Winter R, Connor WE, Steiner RD.

J Inherit Metab Dis. 2012 Sep;35(5):859-69. doi: 10.1007/s10545-012-9453-6. Epub 2012 Mar 6.

11.

Cholesterol level influences opioid signaling in cell models and analgesia in mice and humans.

Zheng H, Zou H, Liu X, Chu J, Zhou Y, Loh HH, Law PY.

J Lipid Res. 2012 Jun;53(6):1153-62. doi: 10.1194/jlr.M024455. Epub 2012 Feb 29.

12.

Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin.

Owens AP 3rd, Passam FH, Antoniak S, Marshall SM, McDaniel AL, Rudel L, Williams JC, Hubbard BK, Dutton JA, Wang J, Tobias PS, Curtiss LK, Daugherty A, Kirchhofer D, Luyendyk JP, Moriarty PM, Nagarajan S, Furie BC, Furie B, Johns DG, Temel RE, Mackman N.

J Clin Invest. 2012 Feb;122(2):558-68. doi: 10.1172/JCI58969. Epub 2012 Jan 3.

13.

Cholesterol regulation of receptor-interacting protein 140 via microRNA-33 in inflammatory cytokine production.

Ho PC, Chang KC, Chuang YS, Wei LN.

FASEB J. 2011 May;25(5):1758-66. doi: 10.1096/fj.10-179267. Epub 2011 Feb 1.

14.

Simvastatin reduces atherogenesis and promotes the expression of hepatic genes associated with reverse cholesterol transport in apoE-knockout mice fed high-fat diet.

Song G, Liu J, Zhao Z, Yu Y, Tian H, Yao S, Li G, Qin S.

Lipids Health Dis. 2011 Jan 18;10:8. doi: 10.1186/1476-511X-10-8.

15.

OxLDL-dependent activation of arginase II is dependent on the LOX-1 receptor and downstream RhoA signaling.

Ryoo S, Bhunia A, Chang F, Shoukas A, Berkowitz DE, Romer LH.

Atherosclerosis. 2011 Feb;214(2):279-87. doi: 10.1016/j.atherosclerosis.2010.10.044. Epub 2010 Nov 4.

16.
17.

Simvastatin enhances immune responses to Aβ vaccination and attenuates vaccination-induced behavioral alterations.

Kou J, Kim HD, Jin J, Cao D, Li L, Lalonde R, Fukuchi K.

Brain Res. 2010 Oct 14;1356:102-11. doi: 10.1016/j.brainres.2010.07.102. Epub 2010 Aug 5.

18.

Targeted disruption of steroidogenic acute regulatory protein D4 leads to modest weight reduction and minor alterations in lipid metabolism.

Riegelhaupt JJ, Waase MP, Garbarino J, Cruz DE, Breslow JL.

J Lipid Res. 2010 May;51(5):1134-43. doi: 10.1194/jlr.M003095. Epub 2009 Nov 17. Erratum in: J Lipid Res. 2010 Jun;51(6):1618.

19.

Simvastatin and tempol protect against endothelial dysfunction and renal injury in a model of obesity and hypertension.

Knight SF, Yuan J, Roy S, Imig JD.

Am J Physiol Renal Physiol. 2010 Jan;298(1):F86-94. doi: 10.1152/ajprenal.00351.2009. Epub 2009 Nov 11.

20.

Simvastatin reverses podocyte injury but not mesangial expansion in early stage type 2 diabetes mellitus.

Wei P, Grimm PR, Settles DC, Balwanz CR, Padanilam BJ, Sansom SC.

Ren Fail. 2009;31(6):503-13.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk